Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C

Hepato-Gastroenterology

Volumn 58, Issue 109, 2011, Pages 1301-1306

  Çoban, Şahin ^a   Idilman, Ramazan ^b   Erden, Esra ^b   Tuz̈un̈, Ali ^b  

^a Diskapi Education and Research Hospital ^*  (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Antiviral agents; Chronic hepatitis C; Gamma glutamyl transpeptidase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 83355170463     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10625     Document Type: Article

References (35)

1. Poynard T, Yuen MF, Ratziu V, Lai CL: Viral hepatitis C. Lancet 2003; 362:2095-2100. (Pubitemid 38035201)
2. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358:958-965. (Pubitemid 32913521)
3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diego M, Marcellin P, et al.: Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Piperno A, Sampietro M, Dalba R, Roffi L, Fargion S, Parma S, et al.: Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16:248-254. (Pubitemid 26290234)
5. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R: Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21:12-17. (Pubitemid 24236674)
6. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D: Effect of anti-viral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53:420-424. (Pubitemid 38241341)
7. Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R: Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-α in chronic HCV infection. J Med Virol 1999; 58:227-234. (Pubitemid 29278024)
8. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075. (Pubitemid 32322537)
9. Villela-Nogueira CA, Perez RM, de Sagadas Soares JA, Coelho HS: Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39:728-730. (Pubitemid 41177095)
10. Benini F, Pigozzi MG, Pozzi A, Bereich L, Reggiani A, Quattrocchi D, et al.: Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis 2009; 41:586-590.
11. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al.: Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609. (Pubitemid 36258782)
12. Itoh S, Nakajima M: Liver gamma-glutamyltransferase activity in viral liver disease. Digestion 1986; 33(3):121-125. (Pubitemid 16213048)
13. Trauner M, Fickert P, Stauber RE: Inflammation-induced cholestasis. J Gastroenterol Hepatol 1999; 14:946-959. (Pubitemid 29487289)
14. Gracielle P, Roberta S, Ornella B, Luciana D, Alessandro R, Daniela Q, et al.: A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA. Hepatol Res 2002; 23:227-236.
15. Baisini O, Gracielle Pigozzi M, Benini F, Stellini R, Reggiani A, Quattrocchi D, et al.: A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C. Hepatol Res 2003; 26:167-173. (Pubitemid 36927189)
16. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al.: Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41:1151-1159. (Pubitemid 40593924)
17. Mazzella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, et al.: Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994; 39:866-870. (Pubitemid 24141794)
18. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al.: Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130:1098-1106.
19. Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys Veer A, et al.: Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27:1217-1225. (Pubitemid 47543150)
20. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al.: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19:1088-1094. (Pubitemid 24134229)
21. Giannini E, Botta F, Fasoli A, Romagnoli P, Mastracci L, Ceppa P, et al.: Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci 2001; 46:524-529. (Pubitemid 32299804)
22. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE: Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004; 19:314-318. (Pubitemid 38338741)
23. Guidi M, Muratori P, Granito A, Muratori L, Pappas G, Lenzi M, Bianchi FB: Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther 2005; 22:943-949. (Pubitemid 41634875)
24. Fabris P, Floreani A, Carlotto A, Baldo V, Bozzola L, Giordani MT, et al.: Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2005; 21:1173-1178. (Pubitemid 40646545)
25. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al.: Obesity and non-alcoholic liver steatosis disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38:705-709. (Pubitemid 39096803)
26. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-490. (Pubitemid 38230851)
27. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR: Effect of significant histologic steatosis or steatohepatitis on response to anti-viral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3:604-609. (Pubitemid 40824754)
28. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al.: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999. (Pubitemid 38670134)
29. Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, et al.: Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon a-2a plus ribavirin. J Viral Hepat 2008; 15:129-136.
30. Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, et al.: Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51:984-990.
31. Nilssen O, Forde OH: Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromso Study. Am J Epidemiol 1994; 139:787-792. (Pubitemid 24135782)
32. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al.: Gamma-glutamyltransferase and diabetes - a 4 year follow-up study. Diabetologia 2003; 46:359-364. (Pubitemid 36547591)
33. Taliani G, Badolato MC, Nigro G, Biasin M, Boddi V, Pasquazzi C, Clerici M: Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C. Clin Immunol 2002; 105:279-285. (Pubitemid 36016055)
34. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J: Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23:210-217. (Pubitemid 26045936)
35. Abacioǧlu YH, Salih Türkoǧlu: Hepatit C virüsü: viroloji ve seroloji. Viral Hepatit 2003. Emin Tekeli, İsmail Balik (Ed). Viral Hepatitle Savaşim Derneǧi Yayini. Ankara, Turkey. 2003: 186-198.